Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Petros Grivas, Neeraj Agarwal, Arlene O. Siefker-Radtke, Stephanie Daignault, Igor Puzanov, Gary R. MacVicar, Ellis Glenn Levine, Sandy Srinivas, Przemyslaw Twardowski, Mario A. Eisenberger, David I. Quinn, Ulka N. Vaishampayan, Evan Y. Yu, Scott Dawsey, Kathleen C. Day, Mark L. Day, David C. Smith, Maha Hussain
Institutions: University of Michigan, University of Utah, Huntsman Cancer Institute, The University of Texas MD Anderson Cancer Center, Vanderbilt University Medical Center, Northwestern University, Roswell Park Comprehensive Cancer Center, Stanford Medicine, City Of Hope National Medical Center, City of Hope, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, USC Norris Comprehensive Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Fred Hutch Cancer Center, U-M Rogel Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2249487864